Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Botox Injection in Upper Esophageal Sphincter for Retrograde Cricopharyngeus Dysfunction
2024-512546-42-00Phase 4Authorised
- Sponsor
- AZ Delta
- Start
- Sep 2024
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in Retrograde Cricopharyngeal Dysfunction (R-CPD) comparing Botox with Placebo (saline) (2 arms). Planned start Sep 2024; status: authorised.
02
Drugs
botulinum toxin type A
03
Conditions
Retrograde Cricopharyngeal Dysfunction (R-CPD)
Beyond the preview
Go deeper on 2024-512546-42-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-512546-42-00.